Endosense, a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, is planning to present update on TactiCath force-sensing ablation catheter at Annual Piper Jaffray Health Care Conference.
The TactiCath force-sensing ablation catheter and its accompanying TactiSys system are indicated for the treatment of atrial fibrillation (AF) and supraventricular tachycardia (SVT).
Endosense in partnership with Biotronik, will provide update on TactiCath’s growing adoption in Europe including progress on the EFFICAS study series aimed at proving superiority of force-sensing catheters over standard irrigated catheters, with first patients having already completed chronic follow-up,
Additionally, update on enrollment in Endosense’s ProForce Registry Study, and investigational device exemption (IDE) trial, Toccastar, which has been filed to the US Food and Drug Administration will also be presented at the conference.
Endosense president and CEO Eric Le Royer said that Endosense has elevated its profile during 2010, as have experienced adoption of their force-sensing catheter among electrophysiologists across Europe, have taken the first step towards entering the US with their PMA filing, and have gathered evidence from TOCCATA trial that twelve month success of ablation procedures is correlated with contact force applied during procedures.